Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News
Price
$2.08
Movement
0.08 (+4.0%)
as at 4 Jun - Closed (20 mins delayed)
52 Week Range
$1.43 - $8.975
1 Year Return
-61.34%
Clarity Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$642.70 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
321.35 million
Earnings per share
-0.163
Dividend per share
N/A
Year To Date Return
-54.56%
Earnings Yield
N/A
Franking
-
Share Price
$2.08
Day Change
0.08 (+4.0%)
52 Week Range
$1.43 - $8.975
Yesterday's Close
$2.00
Today's Open
$2.03
Days Range
$2.02 - $2.11
Volume
1,783,034
Avg. Volume (1 month)
2,970,209
Turnover
$3,706,936
as at 4 Jun - Closed
Clarity Pharmaceuticals Ltd (ASX: CU6)
Latest News
Share Gainers
Why Brainchip, Challenger, Clarity, and Gorilla Gold Mines shares are storming higher
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Fallers
These were the worst ASX 200 shares to own in Q1 2025
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Clarity, New Hope, Orthocell, and West African shares are charging higher today
Healthcare Shares
Why is this ASX 200 healthcare share leaping 14% today?
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today
Healthcare Shares
Guess which ASX 200 biotech stock is jumping 7% on big news
Healthcare Shares
Why is this ASX 200 healthcare share tanking 10% on Tuesday?
CU6 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
CU6 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Jun 2025 | $2.00 | $0.11 | 5.80% | 2,844,113 | $1.91 | $2.02 | $1.86 |
| 02 Jun 2025 | $1.90 | $-0.27 | -12.50% | 4,959,828 | $2.12 | $2.12 | $1.84 |
| 30 May 2025 | $2.16 | $0.00 | 0.00% | 12,178,171 | $2.15 | $2.19 | $2.09 |
| 29 May 2025 | $2.16 | $0.01 | 0.47% | 4,123,158 | $2.20 | $2.37 | $2.12 |
| 28 May 2025 | $2.15 | $-0.06 | -2.71% | 1,892,186 | $2.28 | $2.30 | $2.09 |
| 27 May 2025 | $2.21 | $0.00 | 0.00% | 913,951 | $2.24 | $2.26 | $2.16 |
| 26 May 2025 | $2.21 | $0.01 | 0.45% | 1,036,820 | $2.20 | $2.28 | $2.16 |
| 23 May 2025 | $2.20 | $-0.09 | -3.93% | 989,894 | $2.26 | $2.29 | $2.19 |
| 22 May 2025 | $2.29 | $-0.03 | -1.29% | 949,564 | $2.27 | $2.30 | $2.22 |
| 21 May 2025 | $2.32 | $0.03 | 1.31% | 2,560,062 | $2.32 | $2.50 | $2.31 |
| 20 May 2025 | $2.29 | $0.11 | 5.05% | 2,215,200 | $2.22 | $2.30 | $2.19 |
| 19 May 2025 | $2.18 | $-0.32 | -12.80% | 2,988,356 | $2.40 | $2.41 | $2.17 |
| 16 May 2025 | $2.50 | $-0.02 | -0.79% | 1,405,623 | $2.56 | $2.58 | $2.46 |
| 15 May 2025 | $2.52 | $0.03 | 1.20% | 1,723,734 | $2.49 | $2.58 | $2.40 |
| 14 May 2025 | $2.49 | $-0.07 | -2.73% | 2,286,003 | $2.60 | $2.60 | $2.43 |
| 13 May 2025 | $2.56 | $0.34 | 15.32% | 5,313,209 | $2.28 | $2.68 | $2.28 |
| 12 May 2025 | $2.22 | $-0.21 | -8.64% | 2,845,997 | $2.32 | $2.38 | $2.18 |
| 09 May 2025 | $2.43 | $0.00 | 0.00% | 1,955,204 | $2.46 | $2.53 | $2.37 |
| 08 May 2025 | $2.43 | $0.02 | 0.83% | 2,525,222 | $2.45 | $2.49 | $2.33 |
| 07 May 2025 | $2.41 | $0.04 | 1.69% | 2,722,252 | $2.30 | $2.43 | $2.21 |
| 06 May 2025 | $2.37 | $-0.05 | -2.07% | 3,208,914 | $2.46 | $2.58 | $2.27 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Nov 2024 | Thomas Ramdahl | Issued | 17,080 | $93,018 |
Issue of options. Indicative value of $93,018 using a BlackScholes valuation using the 5-day VWAP
|
| 20 Nov 2024 | Alan Taylor | Issued | 740,748 | $2,041,200 |
Issue of options. Black-Scholes
valuation, Monte Carlo simulation , Indicative value, VWAP |
| 20 Nov 2024 | Rosanne Robinson | Issued | 17,080 | $93,018 |
Issue of options. Indicative value of $93,018 using a BlackScholes valuation using the 5-day VWAP
|
| 20 Nov 2024 | Michelle Parker | Issued | 172,356 | $613,750 |
Issue of options. Black-Scholes valuation, Monte Carlo simulation, vwap, Indicative value
|
| 20 Nov 2024 | Colin Biggin | Issued | 285,918 | $787,875 |
Issue of options. Black-Scholes
valuation, Monte Carlo simulation , Indicative value, VWAP |
| 20 Nov 2024 | Christopher Roberts | Issued | 17,080 | $93,018 |
Issue of options. Indicative value, BlackScholes valuation using the 5-day VWAP
|
| 02 Oct 2024 | Michelle Parker | Buy | 542,710 | $495,000 |
Exercise of options. vwap
|
| 02 Oct 2024 | Michelle Parker | Exercise | 600,000 | $495,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Colin Biggin | Exercise | 1,200,000 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Alan Taylor | Exercise | 1,200,000 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Colin Biggin | Buy | 1,084,321 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Alan Taylor | Buy | 1,083,776 | $990,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Christopher Roberts | Exercise | 200,000 | $165,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Thomas Ramdahl | Buy | 200,000 | $165,000 |
Exercise of options. vwap
|
| 01 Oct 2024 | Christopher Roberts | Buy | 200,000 | $165,000 |
Exercise of options. VWAP
|
| 01 Oct 2024 | Thomas Ramdahl | Exercise | 200,000 | $165,000 |
Exercise of options. vwap
|
| 17 Sep 2024 | Rosanne Robinson | Exercise | 200,000 | $165,000 |
Exercise of options.
|
| 17 Sep 2024 | Rosanne Robinson | Buy | 178,079 | $165,000 |
Exercise of options.
|
| 07 Aug 2024 | Colin Biggin | Buy | 905,625 | $605,000 |
Exercise of options. vwap
|
| 07 Aug 2024 | Colin Biggin | Exercise | 1,000,000 | $605,000 |
Exercise of options. vwap
|
| 01 Aug 2024 | Alan Taylor | Buy | 543,002 | $363,000 |
Exercise of options.
|
| 01 Aug 2024 | Alan Taylor | Exercise | 600,000 | $363,000 |
Exercise of options.
|
| 01 Aug 2024 | Colin Biggin | Buy | 542,835 | $363,000 |
Exercise of options. VWAP
|
| 01 Aug 2024 | Colin Biggin | Exercise | 600,000 | $363,000 |
Exercise of options. VWAP
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Christopher Graham Roberts | Non-Executive Director | Mar 2016 |
Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. He is member of Risk Committee.
|
| Ms Rosanne Elizabeth Robinson | Lead Independent DirectorNon-Executive Director | Oct 2010 |
Ms Robinson brings experience in the nuclear field and a range of commercial and operational expertise to the Group. She has over 25 years of experience in senior leadership and governance roles in public and private companies and government. She is member of Risk Committee.
|
| Dr Alan John Taylor | Executive ChairmanExecutive Director | Nov 2013 |
Dr Taylor has over 15 years of investment banking experience focused predominantly on the life sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory.
|
| Dr Colin David Biggin | Chief Executive OfficerManaging Director | Oct 2019 |
Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo for metastatic prostate cancer, which was approved by the US FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
|
| Ms Michelle Parker | Executive Director | Sep 2024 |
Ms Parker has over 20 years of experience spanning nuclear medicine, positron emission tomography and pharmaceuticals in Australia and internationally. Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia
|
| Mr Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
|
| David Green | Chief Financial Officer |
-
|
|
| Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 22,818,280 | 7.23% |
| UBS Nominees Pty Ltd | 19,336,534 | 6.12% |
| Cabbit Pty Ltd Atf Robwill Trust | 17,911,280 | 5.67% |
| J P Morgan Nominees Australia Pty Limited | 16,935,337 | 5.36% |
| T M Ventures Pty Ltd | 16,699,842 | 5.29% |
| HSBC Custody Nominees (Australia) Limited | 14,248,257 | 4.51% |
| A.C.N. 136 437 913 Pty Ltd Atf The Taylor Family A/C | 13,266,660 | 4.20% |
| Argo Investments Limited | 9,802,322 | 3.10% |
| Yarrawah Pty Ltd Atf Peter Henderson P/L S/F A/C | 8,040,000 | 2.55% |
| Vantres Pty Ltd Atf Asten Super Fund A/C | 6,812,340 | 2.16% |
| Boorris Pty Ltd Atf Boorris Trust | 6,065,800 | 1.92% |
| BNP Paribas Noms Pty Ltd | 5,356,049 | 1.70% |
| Pacific Custodians Pty Limited | 5,280,485 | 1.67% |
| Smarter Capital Pty Ltd | 5,004,543 | 1.58% |
| National Nominees Limited | 4,438,511 | 1.41% |
| Kylaco Pty Ltd | 3,896,280 | 1.23% |
| Bnp Paribas Nominees Pty Ltd | 3,713,550 | 1.18% |
| Australian Nuclear Science & Technology Organisation | 3,599,920 | 1.14% |
| Colin Biggin | 3,249,764 | 1.03% |
| Wyargine Holdings Pty Ltd Atf Shellcove Super Fund | 3,210,425 | 1.02% |